双微创玻璃体手术联合白内障人工晶状体植入的临床效果

目的:观察23G微创玻璃体切割联合1.8mm微切口白内障超声乳化并Ⅰ期植入人工晶状体(IOL)手术的临床效果.方法:回顾性分析2014-09/2015-03在我院行微创玻璃体切割联合微切口白内障超声乳化并Ⅰ期植入IOL手术者共48例54眼.术前、术后5d,1、3mo记录最佳矫正视力(best corrected visual acuity,BCVA)、眼压、角膜散光、角膜内皮细胞计数,观察眼底情况、IOL位置以及术后低眼压、角膜水肿、后发性白内障、高眼压等并发症.结果:所有患者手术均顺利完成.术后3mo BCVA较术前提高49眼(91％),视力无改善5眼(9％),无视力较术前下降者.手术前后眼压、角膜内皮细胞计数差异有显著统计学差异(P＜0.01),术后3 mo角膜内皮细胞丢失率为11.71％±8.12％.角膜散光术后早期增加(P＜0.05),术后3mo与术前无统计学差异(P＞0.05).术后发生一过性高眼压(术后1 mo内眼压＞25mmHg)者6眼,早期角膜水肿发生7眼,前房有成形渗出2眼,发生后囊膜混浊3眼,其中2眼行YAG激光后囊截开术,视力明显提高.术后眼底视网膜均平伏,无发生视网膜脱离、脉络膜脱离、感染性眼内炎、新生血管性青光眼、低眼压患者,无并发IOL偏位、脱位病例.结论:微创玻璃体切割联合微切口白内障超声乳化并Ⅰ期植入IOL手术适应证广泛、损伤小、恢复快、并发症少,是一种安全有效的手术方式,值得推广和应用.     

房角镜辅助下内路360°小梁切开术治疗玻璃体切除术后继发性高眼压

目的：探讨房角镜辅助下内路360°小梁切开术(GATT)治疗玻璃体切除术后继发性高眼压的临床疗效。方法：回顾性研究。纳入2019-01/2022-05在成都市第一人民医院眼科行GATT治疗的玻璃体切除术后继发性高眼压患者10例15眼。记录术前，术后1d，1wk，1、3、6mo最佳矫正视力(BCVA)、眼压、使用的降眼压药物数量及术中、术后并发症，并分析手术成功率。结果：术前和术后6mo时BCVA比较无差异(Z=0，P=1)。术后1d，1wk，1、3、6mo平均眼压17.47±3.78、18.8±3.29、19.13±3.62、20.31±3.66、18.03±3.23mmHg较术前(28.33±9.48mmHg)降低(均P<0.05)； 术后6mo平均用药 1(0，2)种 ，较术前[2(2，4)种]显著下降(P<0.001)； 术后 1d，1wk，1、3、6mo手术总成功率分别为87%(13眼)、93%(14眼)、87%(13眼)、73%(11眼)、93%(14眼)； 术后主要并发症为短暂性前房积血(10眼，67%)，一过性眼压升高(5眼，33%)，未发生其他严重影响视力的并发症。结论：GATT治疗玻璃体切除术后继发性高眼压安全有效。     

Comparison of phacotrabeculectomy and sequential surgery in the treatment of chronic angle-closure glaucoma coexisted with cataract

AIM: To compare the safety and effectiveness of phacotrabeculectomy versus sequential surgery in chronic angle-closure glaucoma (CACG) with coexisting cataract. METHODS: One hundred and sixty-two CACG patients (162 eyes) were retrospectively analyzed. Of them, 87 patients (87 eyes) in group A had underwent phacotrabeculectomy with intraocular lens (IOL) implantation, and 75 patients (75 eyes) in group B had underwent sequential surgery with IOL implanted. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), complications and anterior chamber angle (ACA) were measured. RESULTS: Demographic characteristics of the two groups were similar. A mean follow-up period was 15±6mo (range 13 to 24mo), a mean IOP of 16.61±6.43 mm Hg in group A and 15.80±5.35 mm Hg in group B (P=0.84) at the last follow up. The Kaplan-Meier analysis revealed that the cumulative probability of success in both groups was similar (P=0.61). Anterior uveitis and hypotony were the most common complications in group A, whereas group B experienced shallow anterior chamber with trabeculectomy. With the exception of anterior uveitis, no complications occurred to 11 trabeculectomized eyes. All postoperative measurements of anterior chamber showed statistically significant differences in each group according to the preoperative data (P<0.05). However, fewer changes occurred in group B than in group A. CONCLUSION: Phacotrabeculectomy and sequential surgery exhibit similar IOP reduction, visual recovery, and complications when treating CACG patients with cataract. However, for a wider ACA, phacotrabeculectomy has demonstrated higher effectiveness than sequential surgery.     

Clinical outcomes of 25-gauge vitrectomy surgery for vitreoretinal diseases: comparison of vitrectomy alone and phaco-vitrectomy

AIM: To compare the clinical outcomes of combined 25-gauge pars plana vitrectomy (PPV) and phacoemulsification/posterior chamber intraocular lens (PC-IOL) implantation with vitrectomy alone surgery in patients with various vitreoretinal diseases. METHODS: A total of 306 eyes (145 with PPV alone and 161 with phaco-vitrectomy) were enrolled in this retrospective analysis. The surgical approach was 25-gauge PPV combined with phacoemulsification and PC-IOL implantation at the same time in eyes in phaco-vitrectomy group and only PPV in eyes in vitrectomy alone surgery group. The main outcome measures were postoperative clinical outcomes included anterior chamber inflammation, changes in intraocular pressure (IOP) and best corrected visual acuity (BCVA). RESULTS: The most common postoperative complication was anterior chamber reaction which has higher incidence in phaco-vitrectomy group (P<0.001). The mean postoperative 1st day IOP of vitrectomy alone group was significantly lower than that of phaco-vitrectomy group (16.3±5.8 mm Hg vs 17.8±8.1 mm Hg, respectively, P=0.02). Hypotony (IOP(8 mm Hg) was not different between groups in the postoperative 1st day (P>0.05). The mean preoperative visual acuity was not different between groups (1.6±0.9 logMAR vs 1.8±0.9 logMAR, respectively, P>0.05). However, the mean visual acuity was decreased in vitrectomy alone group at the final visit compared to phaco-vitrectomy group (1.2±0.8 logMAR, 0.9±0.7 logMAR, respectively P<0.05). CONCLUSION: Twenty-five gauge PPV combined with phacoemulsification surgery is a safe and efficient procedure, which can be preferred in phacic patients with a variety of vitreoretinal diseases compared to vitrectomy alone. Despite improved outcomes, this approach is not free of limitations as anterior chamber complications especially with combined surgery.     

27G玻璃体切除原位切膜法治疗晚期增殖性糖尿病视网膜病变

目的：探讨27G玻璃体切除原位切膜法治疗晚期增殖性糖尿病视网膜病变(PDR)的临床疗效。

方法：收集2017-01/08晚期PDR 10例15眼临床病例，行27G微创玻璃体切除术，采用切割头原位切膜法切除增殖膜，观察术中医源性视网膜裂孔发生率、硅油填充率、术前术后最佳矫正视力、眼压等指标。

结果：患者4眼(27%，4/15)术中发生医源性视网膜裂孔； 6眼(40%，6/15)硅油填充； 术后3mo时仅2眼视力不提高，13眼术后视力提高，最好视力0.6，术前最佳矫正视力分别与术后7d，1、3mo最佳矫正视力比较，差异均有统计学意义(P<0.05)； 术前平均眼压16.95±6.87mmHg，术后3mo平均眼压15.27±4.57mmHg，两者比较差异无统计学意义(P>0.05)。

结论：27G玻璃体切除原位切膜法在晚期PDR术中处理视网膜前增殖膜时优势明显，疗效确切，可为晚期复杂PDR的优选术式。     

25G前段玻璃体切除术治疗极浅前房青光眼合并白内障的疗效和安全性

目的：观察巩膜瓣下25G前段玻璃体切除术在超声乳化联合小梁切除术治疗极浅前房青光眼合并白内障中的安全性及有效性。

方法：回顾性分析18例18眼青光眼合并白内障患者(8例男性,10例女性),其中11眼为原发性急性闭角型青光眼,7眼为晶状体半脱位继发青光眼。所有患者经保守治疗后眼压不能控制,均接受白内障超声乳化并人工晶状体植入术、小梁切除术及巩膜瓣下前段玻璃体切除术。主要观察指标为最佳矫正视力、前房深度、眼压、裂隙灯显微镜、降眼压药物、眼底及并发症情况。

结果：患者平均眼轴为21.5±0.6 mm,平均年龄为62.3±7.9岁。术前平均前房深度0.78±0.43 mm,术后1wk平均前房深度2.89±0.41 mm(P<0.001)。术后1wk平均眼压16.72±6.28 mmHg,较术前平均眼压43.28±9.38 mmHg显著下降(P<0.001)。均未发生如眼内炎、视网膜脱离、脉络膜上腔出血、角膜内皮失代偿、恶性青光眼等并发症。

结论：巩膜瓣下25G前段玻璃体切除术在超声乳化联合小梁切除术治疗极浅前房青光眼合并白内障是安全有效的。

     

Wound leakage and hypotony after 25-gauge sutureless vitrectomy: factors affecting postoperative intraocular pressure.

BACKGROUND AND OBJECTIVE: To investigate the factors related to postoperative hypotony after 25-gauge sutureless vitrectomy. PATIENTS AND METHODS: Of 109 consecutive eyes undergoing sutureless vitrectomy, 95 fluid-filled eyes were randomly assigned to three groups according to the order of infusion cannula removal. In group 1 (30 eyes), the infusion was removed first. In group 2 (32 eyes), the infusion was removed after another cannula. In group 3 (33 eyes), the infusion was removed last. Intraocular pressure (IOP) was measured on preoperative day 1 and postoperative days 1, 7, and 30. RESULTS: Mean age was 58.9 +/- 11.6 years (range: 18 to 80 years). Among each factor (including order of infusion removal, age, sex, axial length, preoperative IOP, previous vitrectomy, indications for vitrectomy and lens status), only age was significantly correlated with IOP on postoperative day 1 (P = .019). In 13 eyes in which hypotony persisted through postoperative day 2 (IOP < or = 5 mm Hg), the age of the patients was significantly younger than those who did not experience persisting hypotony (P = .006). CONCLUSION: Younger patients were more likely to experience early postoperative hypotony.     

25G玻璃体切除联合空气填充术治疗孔源性视网膜脱离

目的:观察玻璃体切除联合空气填充术治疗孔源性视网膜脱离的临床疗效,评价空气填充的有效性及安全性。方法:对2017-08/2018-12就诊于遵义市第一人民医院的孔源性视网膜脱离并接受玻璃体切除联合空气填充术的患者30例30眼进行回顾性分析,观察术眼术前、术后1 wk,1 mo最佳矫正视力(BCVA,LogMAR)、眼压、术后视网膜复位情况及术后并发症情况等。结果:术前,术后1wk,1mo BCVA分别为0.87±0.71、0.64±0.36、0.37±0.22,手术前后术眼BCVA有差异(F=3.74,P=0.047)。术前,术后1wk,末次随访眼压分别为13.61±3.57、15.74±4.84、14.05±2.88mmHg,手术前后眼压无差异(F=4.13,P=0.051)。术后1wk视网膜复位率97%(29/30)。术后OCT监测1眼出现持续视网膜下积液,术后3mo积液吸收。结论:玻璃体切除联合空气填充术治疗孔源性视网膜脱离疗效确切,术后恢复快,提高视觉质量,同时减少患者经济负担。     

睫状体光凝术治疗玻璃体切割术后继发青光眼的疗效

目的：评估睫状体光凝术治疗玻璃体切割术后(水眼)继发青光眼的安全性和有效性。

方法：回顾性分析我院2014-10/2016-10收治的玻璃体切割术后(水眼)继发青光眼患者20例20眼的临床资料，对所有患者进行经巩膜睫状体光凝术，术后持续随访3mo，观察术后视力、眼压和并发症情况。

结果：术后1mo时，9眼眼压控制不佳，4眼再次行睫状体光凝术后3眼眼压降至正常。末次随访时，视力较术前差异无统计学意义(P=0.655)； 14眼(70%)患者眼压得到有效控制，眼压(24.6±11.4mmHg)较术前(42.3±5.9mmHg)改善，差异有统计学意义(P<0.05)。术后未出现眼球萎缩、脉络膜上腔出血等严重并发症。

结论：睫状体光凝术对玻璃体切割术后(水眼)继发青光眼患者是一种安全有效、可重复的手术方式。     

Trabeculectomy with anterior vitrectomy in aphakic and pseudophakic glaucoma

In 15 eyes with uncontrolled aphakic/pseudophakic glaucoma, trabeculectomy with anterior vitrectomy was performed. Mean pre-operative intraocular pressure (IOP) was 38.2 ± 6.7 mmHg and mean post operative IOP was 19.3 ± 5.2 mmHg after follow-up of 11.2 2 months. The anterior chamber maintainer technique during vitrectomy has been employed. Success rate (IOP < 21 mmHg with or without glaucoma medication) was 80 %. Visual acuity remained unchanged in 4 eyes, improved in 5 eyes and worsened in 6 eyes. Post-operative complications included: two eyes with cystoid macular edema, two eyes with choroidal effusion and prolonged hypotony, one eye with self-absorbing vitreus hemorrhage and one eye with some opacification of the corneal graft. In aphakic/pseudophakic glaucoma where vitreus is filling the anterior chamber - a combined trabeculectomy with anterior vitrectomy is indicated for removal of vitreus from the sclerostomy site with better aqueous flow through the sclerostomy and adequate control of IOP.     

Comparison of 25-gauge sutureless vitrectomy and 20-gauge vitrectomy in the treatment of posterior capsule opacification in pseudophakic children

AIM: To compare the effectiveness and safety of pars plana capsulotomy and vitrectomy using 25-gauge tansconjunctival sutureless vitrectomy system and 20-gauge vitrectomy system for posterior capsule opacification (PCO) in pseudophakic children. METHODS: Retrospectively study. Pars plana capsulotomy and vitrectomy using 25-gauge sutureless vitrectomy system was performed for PCO in the study group (32 eyes). Patients in the control group (34 eyes) underwent capsulotomy and vitrectomy using standard 20-gauge vitrectomy system, providing a comparison between 2 groups with regard to preoperative and postoperative best corrected visual acuity (BCVA), intraocular pressure (IOP), and intraoperative and postoperative complications. The two groups were performed consequentially. The patients ages ranged from 2 to 13y (means: 6.61±2.73y). Surgical technique, intraoperative and postoperative complications, visual acuity, IOP, and recurrent PCO were recorded. RESULTS: The surgical procedure was performed uneventfully in all patients. Visual acuity improved significantly in both groups. BCVA improved in 22 eyes (81.5%) in the study group and in 28 eyes (87.5%) in the control group. There was no statistical difference of visual acuity that were attainable in two groups (H=0.115, P=0.909). Mean postoperative IOP showed no significant difference between the groups at 1wk. All sort of PCO were accomplished by 20-gauge system, while 25-gauge system was effective for pearls style and 2 grade of fibrous PCO, and was insufficient to grade 3 of PCO. In the study group two cases were not accomplished by 25-gauge system while 20-gauge system conquered them. Compared with the control group, mean operative time for opening and closing the sclerotomy in the study group was considerably reduced. The mean follow-up was 38.2mo (range: 8-79mo). During the follow-up period, no incision leakage, corneal edema, vitreous loss, IOL damage, retinal detachment, recurrent PCO, or other complications were noted. CONCLUSION: Pars plana capsulotomy and vitrectomy using 25-gauge transconjunctival sutureless vitrectomy appeared to be a safe and effective approach for PCO in pseudophakic children. Combined sutureless surgery needed shorter setup time for sclerotomy and caused less surgical trauma than combined surgery with 20-gauge vitrectomy. Therefore, this type of procedure would be a good option for selected cases with PCO in pseudophakic children.     

眼内窥镜下联合手术治疗晚期新生血管性青光眼的疗效

目的：观察小梁切除术结合眼内窥镜技术下前部玻璃体切割术联合视网膜激光光凝术治疗晚期新生血管性青光眼的疗效。方法：对2012-07/2013-07期间在我院住院的15例15眼伴光感以上视力的新生血管性青光眼患者使用小梁切除术结合眼内窥镜技术下前部玻璃体切割术联合视网膜激光光凝术治疗的临床资料进行回顾性分析。结果：所有患者出院后随访6 mo。15例15眼术后1 wk眼压12.53±3.73mmHg (1mmHg=0.133kPa),较术前眼压58.81±5.91 mmHg 明显降低,差异有统计学意义( P<0.05),术后1mo患者平均眼压18.26±4.31mmHg,术后3mo患者平均眼压17.06±3.65mmHg,术后6mo患者平均眼压16.13±3.66mmHg,患者术后随访各时段的眼压与术前比较,差异具有统计学意义(P<0.05)。术后视力提高2例2眼(13%),无变化者11例11眼(73%),视力下降者2例2眼(13%)。随访中有4例4眼眼压增高,使用1~2种降眼压眼药水及局部按摩眼球使得患者眼压<21 mmHg。术后眼部疼痛症状明显缓解。15例15眼虹膜及房角新生血管均有不同程度回退。术后随访眼部B超检查未见眼球萎缩、脉络膜及视网膜脱离。结论：小梁切除术结合眼内窥镜技术下前部玻璃体切割术联合视网膜激光光凝术治疗晚期新生血管性青光眼,能有效降低眼压,挽救患者残存视力,解除疼痛,为一种较安全而有效的治疗方法。     

玻璃体切割手术治疗急性视网膜坏死综合征的长期随访观察

目的 观察玻璃体切割手术(PPV)治疗急性视网膜坏死综合征(ARN)的长期效果.方法 回顾性分析17例ARN患者19只眼接受PPV治疗后随访观察1年及以上的临床资料.所有患者均经临床症状、裂隙灯显微镜以及间接检眼镜检查明确临床诊断.手术前最佳矫正视力(BCVA)无光感～0.1,1只眼为0.1,其中18只眼存在视网膜脱离.19只眼均行常规PPV治疗.19只眼分别接受1～5次手术,平均手术次数2.8次;18只眼接受再次或多次手术,占94.7%.治疗后随访观察12～120个月,平均随访时间44个月.分析首次PPV手术后视网膜复位情况;统计再次或多次手术的主要原因;对比观察治疗前后BCVA、眼压、视网膜以及眼球形态变化.结果 首次PPV手术后第1天17只眼视网膜完全复位.再次或多次手术的主要原因为单纯硅油取出(RSO)、增生性玻璃体视网膜病变(PVR)、低眼压和视网膜脱离.随访期间9只眼BCVA≥0.1,但末次随访时仅4只眼BCVA≥0.1.19只硅油眼的平均眼压12.7 mm Hg(1 mm Hg=0.133 kPa),其中15只眼RSO手术后平均眼压5.1 mm Hg.19只眼PPV手术后均发生了不同程度的PVR.末次随访时8只眼存在不同程度的眼球萎缩.结论 PPV治疗ARN的长期效果较差.     

Long-term observation of vitrectomy without subretinal hemorrhage management for massive vitreous hemorrhage secondary to polypoidal choroidal vasculopathy

AIM: To describe the long-term observation of vitrectomy without subretinal hemorrhage (SRH) management for massive vitreous hemorrhage (VH) secondary to polypoidal choroidal vasculopathy (PCV). METHODS: This is a retrospective, consecutive case series. A total of 86 eyes of 86 patients with >14d of massive VH associated with PCV were included. All patients underwent vitrectomy without SRH management, followed by intravitreal ranibizumab injections and/or photodynamic therapy (PDT) as needed. The main outcome measures were best-corrected visual acuity (BCVA), postoperative adverse events and the recurrence of VH. RESULTS: The average follow-up period was 25.5±9.2mo (range 12-35mo). Mean BCVA at baseline (2.16±0.39 logMAR) had improved significantly, both 3mo after surgery (1.42±0.66 logMAR, P<0.001) and by the last visit (1.23±0.74 logMAR, P<0.001). The common postoperative complications included macular subretinal fibrosis in 14 eyes (16.3%) and ciliary body detachment in 4 eyes (4.7%). Nineteen eyes (22.1%) received following treatment with ranibizumab injections without/with PDT, and 15 (17.4%) were resolved. Four eyes (4.7%) had recurrent hemorrhage during the follow-up period. In multiple regression analysis, thicker SRH (beta=0.33, P=0.025) in the preoperative B-scan and the presence of foveal subretinal fibrosis (beta=0.28, P=0.018) in the follow up were associated with poor postoperative BCVA. CONCLUSION: Vitrectomy without SRH management for massive VH secondary to PCV improved/stabilized visual function in the long-term observation. Eyes presenting with thicker SRH preoperatively and forming foveal subretinal fibrosis in the follow-up period tended to have worse BCVA.     

25G微创玻璃体切除术治疗玻璃体积血的临床观察

目的：探讨25 G微创玻璃体切除术治疗玻璃体积血的临床疗效和安全性。方法：回顾性分析2012-01/2014-06经过视力、眼压、裂隙灯、眼底及B超等检查诊断为玻璃体积血患者200例208眼,所有患者采用25 G 微创玻璃体切除术。比较术前、术后1wk,1、3、6mo最佳矫正视力。观察眼压、前房炎症反应、眼底情况等临床资料。结果：术前视力光感16眼,手动82眼,指数49眼,0.01~0.09者38眼,0.1~0.2者23眼;术后6mo 视力手动1眼,指数2眼,0.01~0.09者31眼,0.1~0.2者29眼,0.2以上者145眼,术后所有患者视力稳定或不同程度提高,手术前后视力差异具有统计学意义( Z=-4.128, P=0.000)。术前平均眼压15.29±3.62mmHg,术后6mo平均眼压13.67±4.93mmHg。其中糖尿病性视网膜病变96眼(46.2％),视网膜分支静脉阻塞37眼(17.8％),视网膜中央静脉阻塞9眼(4.3％),视网膜静脉周围炎13眼(6.25％),息肉样脉络膜视网膜病13眼(6.25％),视网膜大动脉瘤5眼(2.4％),视网膜裂孔19眼(9.1％), Terson综合征16眼(7.7％)。术中联合白内障手术23眼(11.1％),术中玻璃体腔填充灌注液145眼(69.7％), C3F8气体21眼(10.1％),空气17眼(8.2％),硅油25眼(12.0％)。术后并发症：12眼(5.8％)出现术后早期一过性低眼压,8眼(3.8％)术后早期高眼压,19眼(9.1％)出现前房炎症反应,10眼(4.8％)术后早期玻璃体再出血,余所有患者在治疗过程中及治疗后随访均未见眼部或全身不良反应。结论：采用25 G微创玻璃体切除术治疗玻璃体积血是安全有效的,具有创伤小、时间短、恢复快。     

25G玻璃体切除术治疗外伤性白内障的疗效观察

目的：观察25 G玻璃体切除术治疗外伤性白内障的手术疗效。方法：回顾性分析2013－02／2015－02于我院诊治的外伤性白内障行25 G玻璃体切除术联合晶状体切除术的病例70例70眼。男43例43眼,女27例27眼,年龄22～51（平均35．23±2．54）岁,视力平均0．10±0．03。手术后随访时间6～12mo,观察患者的眼前后节、并发症、最佳矫正视力、眼压等,比较患者术前、术后1wk,1、6mo的最佳矫正视力。结果：所有患者均顺利完成手术,视力均有不同程度地提高,术后1wk,1、6mo的最佳矫正视力较手术前比较差异有统计学意义（均P＜0．05）。术后并发症：角膜水肿5例,高眼压10例,低眼压4例,视网膜点状出血5例,经对症支持治疗后,症状均好转。结论：25 G玻璃体切除术联合晶状体切除术能有效治疗外伤性白内障,降低手术风险,减少并发症,提高视力,改善预后。     

Management of hypotony and flat anterior chamber associated with glaucoma filtration surgery

AIM:To determine the effectiveness of pharmacological and interventional treatment of hypotony and flat anterior chamber (FAC) resulting from glaucoma filtration surgery.METHODS:We retrospectively examined the medical records of fifty-two trabeculectomy patients (52 eyes) who developed postoperative hypotony and FAC. The management and associated complications of hypotony, changing intraocular pressure (IOP) and best corrected visual acuity (BCVA) were evaluated.RESULT:Of the 52 patients with hypotony, 29 (56%) had a grade 1 FAC, 21 (40%) had a grade 2 FAC, and only 2 had a grade 3 FAC. There was no significant difference between the mean preoperative IOP and the mean IOP at three and six months after surgery. Thirteen eyes (25%) required antiglaucomatous medication three months after surgery. The mean BCVA at 6mo after surgery was significantly reduced as compared with the mean preoperative BCVA.CONCLUSION:Hypotonia and FAC following trabeculectomy are associated with troublesome complications that require pharmacological and/or surgical treatment. Thus, close follow-up is essential for affected patients.     

玻璃体切除术治疗伴有板层黄斑裂孔相关视网膜前增生膜的全层黄斑裂孔

目的：观察伴有板层黄斑裂孔相关视网膜前增生膜(LHEP)的全层黄斑裂孔(FTMH)患者玻璃体切除术后的视力改善和解剖学闭合情况。方法：回顾性临床病例研究。纳入2018-01/2022-01本院确诊为FTMH患者28例28眼，根据是否有LHEP分为有LHEP组12例12眼，无LHEP组16例16眼。两组患者均行玻璃体切除术治疗。比较两组患者术前、术后1a最佳矫正视力(BCVA)、裂孔愈合情况、椭圆体带和外界膜(ELM)连续性、眼压、术后并发症情况。结果：术前BCVA(LogMAR)有LHEP组为0.80±0.17，无LHEP组为0.92±0.27(t=1.406，P=0.172)； 术后1a有LHEP组为0.54±0.14，无LHEP组为0.39±0.10(t=3.399，P=0.002)。两组患者术后1a BCVA较术前均显著改善(t有LHEP组=4.029，P有LHEP组=0.001； t无LHEP组=7.445，P无LHEP组=0.001)； 两组患者手术前后BCVA(LogMAR)差值有LHEP组为0.27±0.16，无LHEP组为0.52±0.26(t=3.153，P=0.002)。术后1a两组患者裂孔均愈合，愈合率均为100%。有LHEP组20%(2/12)患者椭圆体带闭合，无LHEP组56%(9/16)(P椭圆体带=0.04)； 有LHEP组25%(3/12)患者ELM闭合，无LHEP组69%(11/16)(PELM=0.027)。有LHEP组2眼术后发生一过性的眼压升高，无LHEP组3眼。两组患者玻璃体切除术后均未并发显著白内障及严重并发症。结论：与无LHEP的FTMH患者比较，有LHEP的FTMH患者玻璃体切除术后BCVA提高较小，尽管裂孔愈合，但椭圆体带和ELM闭合率较低，连续性中断持续时间较长，预后需进一步明确。     

25G+微创玻璃体手术治疗人工晶状体植入术后恶性青光眼

目的：观察应用25G+微创玻璃体手术治疗人工晶状体植入术后恶性青光眼的临床效果。

方法：回顾性分析2013-01/2016-07在我科就诊的人工晶状体植入术后恶性青光眼确诊患者18例18眼。术前患眼视力手动～0.5，患眼眼压18.3～56.8(平均35.21±10.43)mmHg，眼轴长度19.60～22.46(平均20.63±0.48)mm，中央前房深度0.98～1.86(平均1.31±0.22)mm。所有患者均接受25G+经睫状体扁平部前部玻璃体切除联合后囊膜切开手术治疗。观察治疗前后患者视力、眼压、前房深度、前房炎症反应及并发症等情况。

结果：术后随访6～12(平均9)mo。末次随访：患者最佳矫正视力0.2～0.8，与术前视力比较差异有统计学意义(P<0.01)； 眼压12.3～19.8(平均16.05±2.46)mmHg，与术前眼压比较差异有统计学意义(t=7.59，P<0.01)； 前房深度1.89～3.49(平均2.42±0.47)mm，与术前前房深度比较，差异有统计学意义(t=9.07，P<0.01)； 术后早期1眼术后眼压为8mmHg，经抗炎治疗恢复正常，末次眼压为15mmHg； 所有患者无角膜内皮细胞失代偿、人工晶状体夹持、眼内出血、感染、眼压失控等严重并发症发生。

结论：25G+微创玻璃体手术可安全有效地治疗白内障术后恶性青光眼。     

Simultaneous pars plana vitrectomy, panretinal photocoagulation, cryotherapy, and Ahmed valve implantation for neovascular glaucoma

AIM: To describe and evaluate the efficacy of Ahmed glaucoma valve implantation (AGV) combined with pars plana vitrectomy (PPV) in a single surgical act for the treatment of advanced neovascular glaucoma (NVG). METHODS: Retrospective observational case series included 51 eyes from 50 patients with severe NVG treated with PPV, AGV, and panretinal photocoagulation and/or cryotherapy in a single surgical act during a 13-year period (2005-2018). Preoperative, intraoperative and postoperative data at day 1 and months 1, 3, 6, 21, and 24 were systematically collected. Definition of surgical success was stablished at IOP between 6 and 21 mm Hg with or without topical treatment. RESULTS: Main indications for surgery were NVG secondary to proliferative diabetic retinopathy (39.2%) and central retinal vein occlusion (37.3%). Mean (±SD) preoperative IOP was 42.0±11.2 mm Hg decreasing to 15.5±7.1 mm Hg at 12mo and 15.8±9.1 mm Hg at 24mo of follow up. Cumulative incidence of success of IOP control was 76.0% at first postoperative month, reaching 88.3% at 6mo. Prevalence of successful IOP control at long term was 74.4% at 12mo and 71.4% at 24mo. Eye evisceration for unsuccessful NVG management was required in 1 case (2.0%). CONCLUSION: Combination of AGV implantation and PPV in a single act may be a suitable option for severe forms of NVG in a case-by-case basis for effective IOP control and a complete panretinal photocoagulation.